Back to top

Analyst Blog

Teva Pharmaceutical Industries Limited (TEVA - Analyst Report) announced that a new dose of its multiple sclerosis (MS) drug, Copaxone (40mg/mL), has been approved by the U.S. Food and Drug Administration (FDA). The drug has been approved for relapsing forms of multiple sclerosis.

This dose of Copaxone allows three times a week subcutaneous administration as compared to the daily administration schedule for the currently available formulation (20 mg/mL). The lower frequency of administration will be more convenient for patients. The three-times-a-week Copaxone will be available within a few days.

New Copaxone Approval, a Major Positive

We view the approval of the new formulation of Copaxone as a major positive for the company. We expect Teva’s shares to gain on the news.

Copaxone generated approximately $3.2 million in sales in the first nine months of 2013, accounting for more than 20% of the company’s total revenues. However, Copaxone could start facing generics this year.

Last month, Teva provided guidance for 2014 based on two likely scenarios related to Copaxone – Copaxone remaining exclusive and Copaxone going generic. The entry of Copaxone generics this year could cut total revenues by about $500 million and earnings by 60 cents.

Teva has undertaken several initiatives (including developing new candidates targeting MS and the new formulation of Copaxone) to mitigate this loss. With MS candidate Nerventra receiving a negative opinion from the Committee for Medicinal Products for Human Use earlier this month, the FDA approval of the new Copaxone formulation comes as a relief.

Teva is planning to switch a significant number of patients (approximately up to 45%) from Copaxone 20 mg/mL to Copaxone 40 mg/mL in the next few months.

However, we remind investors that the competition in the MS market is intense. Apart from injectables, several oral therapies including Novartis’ (NVS - Analyst Report) Gilenya and Biogen Idec’s (BIIB - Analyst Report) Tecfidera are also available.

Teva carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks include Actavis (ACT - Analyst Report) carrying a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.22 +27.84%
TRIQUINT SE… TQNT 20.83 +7.37%
VASCO DATA… VDSI 14.83 +5.10%
CENTURY ALU… CENX 25.79 +4.82%
TESLA MOTOR… TSLA 276.07 +4.63%